Free tool
FAERS Monitor: Tamiflu
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021246 or its brand name (Tamiflu, Oseltamivir Phosphate). Reports on generic versions are filed under their own applications.
Reports
18,140
Serious
11,193
62% of reports
Hospitalization
4,480
Death reported
1,814
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- vomiting1,886
- nausea1,364
- no adverse event1,058
- influenza963
- abnormal behaviour927
- diarrhoea867
- dyspnoea863
- hallucination827
- pyrexia746
- headache678
- drug ineffective648
- pneumonia644
- off label use618
- rash610
- cough600
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 153 |
| 2005 | 393 |
| 2006 | 278 |
| 2007 | 546 |
| 2008 | 351 |
| 2009 | 1,569 |
| 2010 | 1,311 |
| 2011 | 477 |
| 2012 | 518 |
| 2013 | 550 |
| 2014 | 475 |
| 2015 | 1,361 |
| 2016 | 1,136 |
| 2017 | 1,867 |
| 2018 | 1,599 |
| 2019 | 1,157 |
| 2020 | 1,013 |
| 2021 | 405 |
| 2022 | 380 |
| 2023 | 525 |
| 2024 | 1,174 |
| 2025 | 556 |
| 2026 | 345 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,036,019 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| abnormal behaviourSignal | 927 | 27.8 | 26.0 | 23,370 |
| hallucinationSignal | 827 | 12.9 | 12.0 | 8,961 |
| influenzaSignal | 963 | 10.1 | 9.5 | 7,852 |
| no adverse eventSignal | 1,058 | 6.8 | 6.4 | 5,247 |
| vomitingSignal | 1,886 | 4.7 | 4.5 | 5,530 |
| pyrexiaSignal | 746 | 2.5 | 2.3 | 682 |
| coughSignal | 600 | 2.5 | 2.3 | 536 |
| pneumoniaSignal | 644 | 2.3 | 2.1 | 483 |
| nausea | 1,364 | 2.0 | 1.9 | 706 |
| dyspnoea | 863 | 1.8 | 1.7 | 295 |
| rash | 610 | 1.6 | 1.5 | 148 |
| diarrhoea | 867 | 1.6 | 1.5 | 178 |
| headache | 678 | 1.3 | 1.2 | 36 |
| off label use | 618 | 0.8 | 0.8 | 26 |
| drug ineffective | 648 | 0.6 | 0.5 | 224 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.